NOTE: Please save this file locally before filling in the table, DO NOT work on the file within your internet browser as changes will not be saved. Adobe Acrobat Reader (available free here) is recommended for completion.

The ARRIVE guidelines 2.0: author checklist

The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

Item		Recommendation	Section/line number, or reason for not reporting
Study design	1	For each experiment, provide brief details of study design including: a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated. b. The experimental unit (e.g. a single animal, litter, or cage of animals).	Methods section page 12 paragraph 2 line 248; Introduction section, page 5 , paragraph 3 line 95, this is a feasability and safety study therefore there is no control group. Methods section, page 12 paragraph 2 line 248;page 6 line 108 paragraph 1
Sample size	2	a. Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used. b. Explain how the sample size was decided. Provide details of any *a priori* sample size calculation, if done.	Methods section, page 12 , paragraph 2, line 248; NA since this is a feaisability study no formal calculation of sample size was requiered
Inclusion and exclusion criteria	3	a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were established *a priori.* If no criteria were set, state this explicitly. b. For each experimental group, report any animals, experimental units or data points not included in the analysis and explain why. If there were no exclusions, state so. c. For each analysis, report the exact value of *n* in each experimental group.	Methods section, page 6 paragraph 1, line 108, Swine weight criteria Methods section, page 9 paragraph 1 lines 180; page 13 paragraph 1, line 304; Tables section line 510; Tables section, page 24 paragraph 1 line 531
Randomisation	4	a. State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence. b. Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.	N/A. This was a feasibility and safety study of new method and there was no control group. NA this is feasabilty study without control
Blinding	5	Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	N/A. The study was not blinded.
Outcome measures	6	a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes). b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.	Introduction section,page 5 paragraph 3, line 95 N/A. It is a feasibility study and not a hypothesis-testing study.
Statistical methods	7	a. Provide details of the statistical methods used for each analysis, including software used. b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.	Methods section,page 14 paragraph 1 line 293 Methods section,page 14 paragraph 1 line 293
Experimental animals	8	a. Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight. b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.	Methods section,page 6 paragraph 1 line 103,page 9 paragraph 2 line 203 Methods section, page 6 paragraph 1 line 103 page 9 paragraph 2 line 203
Experimental procedures	9	For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including: a. What was done, how it was done and what was used. b. When and how often. c. Where (including detail of any acclimatisation periods). d. Why (provide rationale for procedures).	Merhods section page 6 paragraph 3 line 123-230, page 12 paragraph 1 248-270 Merhods section page 6 paragraph 3 line 123-230, methods section page 12 paragraph 1 line 248-270 Merhods section page 6 paragraph 3 line 123-230, methods section page 12 paragraph 1 line 248-270 Merhods section page 6 paragraph 3 line 123-230, methods section page 12 paragraph 1 line 248-270
Results	10	For each experiment conducted, including independent replications, report: a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range). b. If applicable, the effect size with a confidence interval.	Table 3, page 11 paragraph 2 Stabiliy analysis, line 259 NA confidence interval was not needed

The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

Item		Recommendation	Section/line number, or reason for not reporting
Abstract	11	Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions.	Abstract section page 2 paragraph 2,line 27
Background	12	a. Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach. b. Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology.	Introduction section,page 3 paragraph 3 line 50 Abstract section page 3 paragraph 1 line, 33
Objectives	13	Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.	Intorduction section page 5 paragraph 3 line 95
Ethical statement	14	Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification.	Methods section,page 6 paragraph 1 line 104
Housing and husbandry	15	Provide details of housing and husbandry conditions, including any environmental enrichment.	Methods p6 par. 2 line 113. p10 par. 2 line 203
Animal care and monitoring	16	a. Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress. b. Report any expected or unexpected adverse events. c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this.	Methods section,page 6 paragraph 3 line 123 Results section,page 15 paragraph 3 line 366 Methods section, page 10 paragraph 2 line 203
Interpretation/ scientific implications	17	a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature. b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results.	Discussion section,page 18 pragraph 2 line 394 Discussion section, page 18 paragraph 3 line 405
Generalisability/ translation	18	Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate).	Conclusions section,page 19 paragraph 4 line 431
Protocol registration	19	Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered.	Methods section ,paragraph 1 page 6 line 107 A protocol was prepared before the study without registration. Protocols were prepared before the study and approved by the Montefiore Medical Center Institutional Animal Care and Use Committee (IACUC) (study protocols#20-11-100 and
Data access	20	Provide a statement describing if and where study data are available.	Data Sharing Statement
Declaration of interests	21	a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated. b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study.	COI section line 446 page 20 paragraph 2 Acknowledgment section page 20 paragraph 1 line 437

Article information: https://dx.doi.org/10.21037/tlcr-23-639